Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: The MACHT observational study

Blood Pressure

Volumn 15, Issue SUPPL. 1, 2006, Pages 27-32

  Abts, Markus ^a   Claus, Volker ^b   Lataster, Marcos ^c  

^a Arzt für Allgemeinmedizin ^*  (Germany)

^b INPUT Clinical Research GmbH   (Germany)

^c Novartis Pharma Deutschland   (Germany)

Author keywords

Angiotensin receptor blocker; Hydrochlorothiazide; Hypertension; Observational; Valsartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EPIGASTRIC PAIN; ERECTILE DYSFUNCTION; FACE EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEADACHE; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; XEROSTOMIA;

AGED; BLOOD PRESSURE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 33644807201     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08038020510046698     Document Type: Article

References (8)

1. In. Deutsche Liga zur Bekämpfung des hohen Blutdrucks e.V. Leitlinien für die Pra7die;vention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. AWMF Leitlinien-Register Nr. 046/ 001; 2003
2. Guideline Committee. (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21, pp. 1011 - 1053.
3. Chobanian, A. V. and Bakris, G. L. and Black, H. R. and Cushman, W. C. and Green, L. A. and Izzo, J. L Jr. and (2003) The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA, 289, pp. 2560 - 2572.
4. Law, M. R. and Wald, N. J. and Morris, J. K. and Jordan, R. E. (2003) Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ, 326, pp. 1427.
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blockers vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288, pp. 2981 - 2997.
6. Guidelines Subcommittee. (1999) 1999 World Health Organization - International Society of Hypertension. Guidelines for the Management of Hypertension. J Hypertension, 17, pp. 151 - 183.
7. World Health Organization.. Obesity epidemic puts millions at risk from related diseases. Press Release WHO/46, 12 June 1997
8. Schwandt, P. (2003) Effektive Blutdrucksenkung - Die Kombination machts. Cardiovasc, 6, pp. 48.